CCO inPractice Hepatology Apps Now Available 

CCO inPractice Hepatology apps are now available for iPad, iPhone, and Android. You can download inPractice to your mobile device for FREE and get the benefit of using inPractice at the point of care.

Highlights From Barcelona 2012
In this downloadable slideset, Graham R. Foster, FRCP, PhD; David R. Nelson, MD; and Stefan Zeuzem, MD, review the most clinically relevant new data from the 2012 annual meeting of the European Association for the Study of the Liver.

Clinical Implications of HCV Resistance
Graham R. Foster, FRCP, PhD, provides expert opinion on how to avoid the development of HCV resistance with new direct-acting antiviral regimens through review of 4 patient cases.

Clinical Implications of HCV Resistance
Graham R. Foster, FRCP, PhD, provides expert opinion on how to avoid the development of HCV resistance with new direct-acting antiviral regimens.

Clinical Implications of HCV Resistance: Laying the Foundation for Optimal Treatment Today and in the Future
Join Stephane Chevaliez, PharmD, PhD; Paul J. Pockros, MD; and Stefan Zeuzem, MD, as they review and discuss key principles of HCV resistance with currently approved direct-acting antiviral agents, the latest resistance data on agents in development, and important considerations for potential future anti-HCV regimens. These expert faculty members also provide practical strategies for clinical challenges with the newly approved direct-acting agents through a case-based analysis.

Hepatitis B Reactivation: A Largely Preventable Problem
In this Interactive Virtual Presentation, Jordan J. Feld, MD, MPH, defines HBV reactivation, the populations for whom HBV screening is recommended, and appropriate steps for treating and monitoring patients to prevent HBV reactivation.

Hepatitis B Reactivation: A Largely Preventable Problem
In this downloadable slideset, Jordan J. Feld, MD, MPH, highlights the real potential for HBV reactivation in patients undergoing chemotherapy or immunosuppressive therapy, and outlines strategies for appropriate screening, treatment, and management.

The Beckoning Future: How Hepatitis C Drugs in Development May Affect Practice Today and Tomorrow
Review the current benefits and limitations with protease inhibitor-based HCV therapies, and the emerging data on potential future regimens and the advances they represent.

The New Elements of HCV Care: Practical Skills to Optimize Protease Inhibitor–Based Therapy
Review the approved indications and proper management of HCV-infected patients with the newly approved protease inhibitors.

The New Elements of HCV Care: Practical Skills to Optimize Protease Inhibitor–Based Therapy
Join Graham R. Foster, FRCP, PhD; Paul Y. Kwo, MD; and Fred Poordad, MD, as they discuss optimal management strategies for 8 case scenarios of patients considering or receiving treatment with boceprevir or telaprevir.

Understanding the Optimal Use and Interpretation of Assays in HCV
In this Interactive Virtual Presentation, Paul Y. Kwo, MD, provides practical recommendations regarding the use of the various HCV assays available to guide the management of patients considering or already receiving treatment.

Understanding the Optimal Use and Interpretation of Assays in HCV
In this Downloadable Slideset, Paul Y. Kwo, MD, provides practical recommendations regarding the use of the various HCV assays available to guide the management of patients considering or already receiving treatment.

Understanding the Optimal Use and Interpretation of Assays in HCV
In this downloadable resource, Paul Y. Kwo, MD, reviews the role of HCV RNA assays in managing patients receiving boceprevir or telaprevir.

A Practical Guide for the Use of Boceprevir and Telaprevir for the Treatment of Hepatitis C
With the advice of a panel of experts, this practical guide has been prepared as a consensus recommendation for how telaprevir and boceprevir should be used in the treatment of patients with HCV infection.

A Practical Guide for the Use of Boceprevir and Telaprevir for the Treatment of Hepatitis C
In this downloadable slideset, a panel of HCV experts outline the optimal use of boceprevir and telaprevir in the treatment of hepatitis C.

Opportunities and Challenges in HCV Management
In this downloadable slideset, Elizabeth Britton, MSN, reviews the key elements of HCV management for NPs and PAs.

Pocket Guide for Using Telaprevir and Boceprevir
Download this quick reference guide highlighting the key elements of care when using boceprevir and telaprevir in clinical practice.

Direct-Acting Antivirals in Treatment-Naive HCV Patients
Mark S. Sulkowski, MD, reviews the latest data on and the approved indications of telaprevir and boceprevir in treatment-naive, genotype 1 HCV–infected patients.

Recent Advances in Antiretroviral Therapy
Joel E. Gallant, MD, MPH, reviews state-of-the-art management of antiretroviral therapy and discusses the clinical implication of recent data for HIV-infected patients.

HCV Resistance: Similarities and Differences With HIV 
Stuart Ray, MD, reviews key similarities and differences between the life cycles and resistance mechanisms of HCV and HIV and explores how these features may impact HCV treatment with newly approved direct-acting antiviral agents.

Healthcare Reform and HIV Care
Michael T. Wong, MD, discusses the healthcare reform measures of 2010 and potential impact on HIV treatment.

Direct-Acting Antivirals in Treatment-Experienced HCV Patients
Ira M. Jacobson, MD, reviews the key data and optimal use of protease inhibitor therapy in treatment-experienced individuals with HCV infection.

Management of Aging HIV-Infected Patients
Amy C. Justice, MD, MSc, PhD, discusses the aspects of HIV management affected by aging and describes use of the VACS Index, a tool that may be used to stratify risk in aging patients.

2011 HIV/Hepatitis C Annual Update
Download this slideset of selected key figures and tables from the CCO HIV and Hepatitis C Annual Update for use in your personal noncommercial presentations.

Epidemiology, Screening, and Predictors of Response in HCV
Watch, listen, and test your knowledge as Peter Ferenci, MD, reviews the latest information on the epidemiology of HCV, screening recommendations, and baseline predictors of response to therapy.

On-Treatment Management of Patients With Hepatitis C
In this Interactive Virtual Presentation, Graham R. Foster, FRCP, PhD, provides a case-based review of optimal strategies for on-treatment management of patients undergoing therapy for chronic hepatitis C, including an assessment of key decision points during protease inhibitor–based therapy.

Strategies to Maintain Quality of Life and Minimize Adverse Events in Patients Receiving Hepatitis C Therapy
In this Interactive Virtual Presentation, Mitchell L. Shiffman, MD, provides a case-based overview of practical strategies that clinicians can implement to improve outcomes among their patients receiving treatment for chronic hepatitis C, with a focus on the new challenges arising during treatment with HCV protease inhibitor–based regimens.

Epidemiology, Screening, and Predictors of Response in HCV
In this downloadable slideset, Peter Ferenci, MD, reviews the burden of HCV, recommendations and challenges related to HCV screening, strategies for counseling patients on treatment candidacy, key baseline predictors of response to HCV therapy, and the potential impact of newly approved therapies on HCV management.

On-Treatment Management of Hepatitis C Patients
In this downloadable slideset, Graham R. Foster, FRCP, PhD, provides a case-based review of optimal strategies for on-treatment management of patients undergoing therapy for chronic hepatitis C, including an assessment of key decision points during protease inhibitor–based therapy.

Strategies to Maintain Quality of Life and Minimize Adverse Events in Patients Receiving Hepatitis C Therapy
In this downloadable slideset, Mitchell L. Shiffman, MD, outlines practical strategies that clinicians can implement to improve outcomes among their patients receiving treatment for chronic hepatitis C, with a focus on the new challenges arising during treatment with HCV protease inhibitor–based regimens.

Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B
In this Interactive Virtual Presentation, Robert G. Gish, MD, provides case-based guidance on the optimal use of virologic and serologic tests in the diagnosis and management of hepatitis B.

Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B
In this Downloadable Slideset, Robert G. Gish, MD, provides guidance on the optimal use of virologic and serologic tests in the diagnosis and management of hepatitis B.

Algorithm for Management of Chronic HBV Infection
Albert Min, MD, provides a detailed algorithm for the management of chronic hepatitis B infection.

HBV Treatment and Everyday Realities —Volume 1, Edition 2
Video and audio podcasts of hot topics and practical strategies in the management, treatment, and care of patients with chronic viral hepatitis, including those with advanced liver disease.  Click here to start.